This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other ...
Consequently, NIPEP-TPPs enable the creation of peptide–drug conjugates (PDCs) that, depending on the targeting moiety, can be selectively delivered to almost any specific cell or tissue with hi ...
Primary target patient population for the CBX-12 Phase 2 study is women with platinum-resistant or refractory ovarian cancer who are naïve to ...
Oct. 07, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) therapeutics ...
Scientists from China have investigated how short peptide chains aggregate together in order to deepen our understanding of ...
Sept. 16, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC) therapeutics ...
AZoLifeSciences on MSN1mon
Insights into Peptide Clumping Could Transform Drug Design and Material ScienceScientists from China have investigated how short peptide chains aggregate together in order to deepen our understanding of ...
Oct. 07, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) therapeutics ...
Register to read this story and more for free. Signing up for an account helps us improve your browsing experience.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback